dalbavancin

Dalbavancin (BI-397), a novel second-generation lipoglycopeptide antibiotic, possesses in vitro activity against a variety of Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE),Dalbavancin inhibits Staphylococcus aureus and Bacillus anthracis with MIC90s of 0.06 μg mL and 0.25 μg mL, respectively

Dalbavancin hydrochloride (MDL-63397 hydrochloride), a semisynthetic lipoglycopeptide antibiotic, demonstrates potent bactericidal effects against Gram-positive bacteria. It effectively inhibits Staphylococcus aureus and Bacillus anthracis with minimum inhibitory concentrations (MIC 90) of 0.06 μg mL and 0.25 μg mL, respectively [1] [2].

A40926 (Dalbavancin Impurity) is effective against Gram positive bacteria.

Parvodicin C2, a glycopeptide antibiotic derived from A. parvosata and part of the parvodicin complex, serves as a component of the A40926 antibiotic complex utilized as a precursor for synthesizing dalbavancin. It exhibits activity against methicillin-sensitive and methicillin-resistant strains of S. aureus, S. epidermidis, S. saprophyticus, S. hemolyticus, and E. faecalis.